Jeannette Bouchard

Jeannette Bouchard

Auto-generated profile, based on publicly available information

Jeannette Bouchard

Duke Antimicrobial Stewardship Outreach Network (DASON) Durham North Carolina USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
KPKelly E. Pillinger
Kelly E. Pillinger
JBJeannette Bouchard
Jeannette Bouchard
SWSarah T. Withers
Sarah T. Withers
KMKrutika Mediwala
Krutika Mediwala
EMEdoabasi MCGEE
Edoabasi MCGEE
P. Brandon BookstaverP. Brandon Bookstaver
P. Brandon Bookstaver
Objective: To review the use of antibiotic stewardship interventions in the adult oncology and hematopoietic cell transplantation (HCT) populations. Data Sources: A literature search of PubMed was performed from inception to October 31, 2019. The general search terms used were oncology, cancer, hematologic malignancy, antimicrobial stewardship, antibiotic stewardship, febrile neutropenia, neutropenic fever, de-escalation, discontinuation, prophylaxis, practice guidelines, clinical pathway, rapid diagnostics, Filmarray, Verigene, MALDI-TOF, antibiotic allergy, and antimicrobial resistance. Study Selection and Data Extraction: Relevant English-language studies describing interventions supported by the Infectious Diseases Society of America guidelines on “Implementing an Antibiotic Stewardship Program” were included. Data Synthesis: Antibiotic stewardship publications in the oncology population have increased in recent years. Studies have described the impact of stewardship interventions, including preauthorization, prospective audit and feedback, implementation of clinical pathways, de-escalation of empirical antibiotics for febrile neutropenia (FN) prior to neutrophil recovery, allergy assessments, and use of rapid diagnostic testing. Many of these interventions have been shown to decrease antibiotic use without increased negative consequences, such as affecting length of stay or mortality. Relevance to Patient Care and Clinical Practice: This review synthesizes available evidence for implementing antibiotic stewardship interventions, particularly de-escalation of antibiotics for FN and implementation of clinical pathways for FN and sepsis, in oncology patients and HCT recipients. Summary tables highlight studies and specific research needs for clinicians. Conclusions: Immunocompromised populations, including oncology patients, have often been excluded from stewardship studies. Antibiotic stewardship is effective in reducing antibiotic consumption and improving outcomes in this patient population, although more quality data are needed.

24 June 2020 in Pharmacy
Verified
Journal Article
Open access
PDF file
JHJeffrey Hall
Jeffrey Hall
JBJeannette Bouchard
Jeannette Bouchard
P. Brandon BookstaverP. Brandon Bookstaver
P. Brandon Bookstaver
MHMatthew S. Haldeman
Matthew S. Haldeman
PKPeter Kishimbo
Peter Kishimbo
ANAnthony Nsojo
Anthony Nsojo
Background: In 2017, Mbeya Zonal Referral Hospital (MZRH) and the University of South Carolina (UofSC) agreed to collaboratively strengthen antimicrobial prescribing in the southern highlands of Tanzania and train a new generation of clinicians in responsible antimicrobial use. Methods: Key stakeholders and participants were identified and the Mbeya Antimicrobial Stewardship Team (MAST) was created. The team identified assets brought by the collaborators, and four investigations of baseline needs were developed. These investigations included (a) a baseline clinician survey regarding antimicrobial resistance and stewardship, (b) a serial chart review of inpatient antimicrobial prescribing practices, (c) an investigation of antimicrobial resistance rates using existing isolates at the MZRH laboratory, and (d) a survey of antimicrobial availability at community pharmacies in the city. Results: 91% of physicians believe antimicrobial resistance is problem in Tanzania, although only 29% of physicians were familiar with the term “antimicrobial stewardship”. Escherichia coli isolates had resistance rates of over 60% to the commonly used agents ciprofloxacin, trimethoprim-sulfamethoxazole, and ceftriaxone. Thirteen out of 14 community pharmacies offered over-the-counter antibiotics for upper respiratory symptoms. Conclusions: International antimicrobial stewardship collaborations can successfully identify opportunities and needs. Evaluating the team’s efforts to improve patient outcomes will be essential.

18 November 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KWKristen Whelchel
Kristen Whelchel
AZAutumn D. Zuckerman
Autumn D. Zuckerman
DKDavid E Koren
David E Koren
CDCaroline Derrick
Caroline Derrick
JBJeannette Bouchard
Jeannette Bouchard
CCCody A Chastain
Cody A Chastain
Limited data exist regarding the use of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) in patients who are unable to swallow tablets. This case series describes HCV treatment in patients requiring tablet manipulation, providing evidence for safety and effectiveness of HCV DAA tablet manipulation.

27 February 2023 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
MHMargaret R. Hitchins
Margaret R. Hitchins
JBJeannette L. Bouchard
Jeannette L. Bouchard
CIChristopher W. Ingram
Christopher W. Ingram
AOAlison I. Orvin
Alison I. Orvin
Objective: We evaluated the impact of an asymptomatic bacteriuria (ASB) assessment protocol on the number of antibiotics prescribed for ASB after discharge from the emergency department (ED). Design: Single-center, before-and-after, retrospective cohort study. Setting: The study was conducted at a large community health system in North Carolina. Patients: Eligible patients were discharged from an ED without an antibiotic prescription and had a positive urine culture result after discharge from May through July 2021 (preimplementation group) and October through December 2021 (postimplementation group). Methods: Patient records were reviewed to determine the number of antibiotic prescriptions for ASB on follow-up call before and after implementation of an ASB assessment protocol. Secondary outcomes included 30-day admissions, 30-day ED visits, 30-day UTI-related encounters, and projected antibiotic days of therapy. Results: The study included 263 patients: 147 in the preimplementation group and 116 in the postimplementation group). There were significantly fewer antibiotic prescriptions for ASB in the postimplementation group (50% vs 8%; P < .0001). There were no differences in the incidence of 30-day admissions (7% vs 8%; P = .9761), 30-day ED visits (14% vs 16%; P = .7805), or 30-day UTI-related encounters (0% vs 0%, NA). Conclusions: Implementation of an ASB assessment protocol for patients discharged from the ED significantly reduced the number of antibiotic prescriptions for ASB on follow-up call without an increase in 30-day admissions, ED visits, or UTI-related encounters.

24 October 2021 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
PDF file
NPNimish Patel
Nimish Patel
JBJeannette Bouchard
Jeannette Bouchard
MOMeredith B. Oliver
Meredith B. Oliver
MBMelissa E Badowski
Melissa E Badowski
JCJoseph J. Carreno
Joseph J. Carreno
TPThe Society Of Infectious Diseases Pharmacists
The Society Of Infectious Diseases Pharmacists
As of August 2021, there were three COVID‐19 vaccines available in the United States for the prevention of coronavirus 2019 (COVID‐19). The purpose of this narrative review is to examine the early experience from the Emergency Use Authorization (EUA) of BNT162b2 (Pfizer, Inc./BioNTech), mRNA‐1273 (Moderna, Inc.), and Ad26.COV2.S (Johnson and Johnson/Janssen Global Services, LLC) through July 2021. The EUA data from the clinical trials have largely been corroborated by real‐world effectiveness investigations post‐authorization. These studies indicate that immunity is obtained within 2 weeks post‐vaccination and may endure for 6 months. The immunity conferred by the vaccines may also be effective against SARS‐CoV‐2 variants of concern. Additionally, populations not included in the emergency use authorization studies may also benefit from vaccination. This look back at the initial clinical experience can be used by the global community to inform and develop COVID‐19 vaccine programs.

1 December 2022 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
MHMargaret Hitchins
Margaret Hitchins
KOKeliana O'MAra
Keliana O'MAra
LELaura Edwards
Laura Edwards
JBJeannette Bouchard
Jeannette Bouchard